• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Elelyso
    / Pfizer

    Active Ingredient
    Taliglucerase Alfa 200 U/vial

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1X 200 U

    partial basket chart 26152 5557

    Related information


    Recommended Dosage: Treatment-naïve patients: The recommended dosage for treatment-naïve adult and pediatric patients above 2 years of age and older is 60 units per kg of body weight administered every other week as a 60 to 120 minute intravenous infusion.
    Patients switching from imiglucerase: Patients currently being treated with imiglucerase for Type 1 Gaucher disease can be switched to Taliglucerase Alfa. Patients previously treated on a stable dosage of imiglucerase are recommended to begin treatment with Taliglucerase Alfa at that same dosage when they switch from imiglucerase to Taliglucerase Alfa Dosage adjustments can be made based on achievement and maintenance of each patient’s therapeutic goals.
    Taliglucerase Alfa should be reconstituted, diluted, and administered under the supervision of a healthcare professional. For preparation and administration instructions – See prescribing information.


    Taliglucerase alfa for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults and pediatric patients above 2 years with a confirmed diagnosis of Type 1 Gaucher disease.


    Hypersensitivity to the active substance or to any of the excipients.

    Special Precautions

    Serious hypersensitivity reactions, including anaphylaxis, have occurred in some patients treated with Taliglucerase alfa. Signs and symptoms of these patients included urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, and dizziness. These reactions occurred during Taliglucerase alfa infusion.
    See prescribing information for full details.

    Side Effects

    Headache, arthralgia, fatigue, vomiting.
    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    Pregnancy and Lactation

    Pregnancy: There are no adequate and well-controlled studies of Taliglucerase alfa in pregnant women.
    LactationIt is not known whether Taliglucerase alfa is present in human milk.
    See prescribing information for full details.


    See prescribing information for full details.

    Important notes

    Storage: Store Taliglucerase alfa under refrigeration at 2° C to 8° C. Do not freeze. Protect vials from light.
    See prescribing information for full details.

    Pfizer global manufacturing USA